AUTOLUS THERAPEUTICS PLC (AUTL)
US05280R1005 - ADR
Overall AUTL gets a fundamental rating of 3 out of 10. We evaluated AUTL against 588 industry peers in the Biotechnology industry. AUTL has a great financial health rating, but its profitability evaluates not so good. AUTL is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year AUTL has reported negative net income.
In the past year AUTL has reported a negative cash flow from operations.
In the past 5 years AUTL always reported negative net income.
AUTL had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -55.51%, AUTL perfoms like the industry average, outperforming 45.22% of the companies in the same industry.
AUTL has a Return On Equity of -186.93%. This is in the lower half of the industry: AUTL underperforms 70.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.51% | ||
| ROE | -186.93% | ||
| ROIC | N/A |
ROA(3y)-40.3%
ROA(5y)-42%
ROE(3y)-94.04%
ROE(5y)-79.68%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for AUTL so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
AUTL does not have a ROIC to compare to the WACC, probably because it is not profitable.
There is no outstanding debt for AUTL. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
AUTL has an Altman-Z score of -1.66. This is a bad value and indicates that AUTL is not financially healthy and even has some risk of bankruptcy.
AUTL has a Altman-Z score (-1.66) which is comparable to the rest of the industry.
AUTL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.66 |
ROIC/WACCN/A
WACC8.67%
2.3 Liquidity
AUTL has a Current Ratio of 6.15. This indicates that AUTL is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of AUTL (6.15) is better than 63.48% of its industry peers.
A Quick Ratio of 6.15 indicates that AUTL has no problem at all paying its short term obligations.
AUTL's Quick ratio of 6.15 is fine compared to the rest of the industry. AUTL outperforms 63.82% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.15 | ||
| Quick Ratio | 6.15 |
3. Growth
3.1 Past
AUTL shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 23.52%, which is quite impressive.
The Revenue for AUTL has decreased by -73.31% in the past year. This is quite bad
AUTL shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 3.79% yearly.
EPS 1Y (TTM)23.52%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-95.65%
Revenue 1Y (TTM)-73.31%
Revenue growth 3Y-0.43%
Revenue growth 5Y3.79%
Revenue growth Q2Q-100%
3.2 Future
The Earnings Per Share is expected to grow by 17.58% on average over the next years. This is quite good.
Based on estimates for the next years, AUTL will show a very strong growth in Revenue. The Revenue will grow by 192.07% on average per year.
EPS Next Y45.49%
EPS Next 2Y27.37%
EPS Next 3Y28.06%
EPS Next 5Y17.58%
Revenue Next Year1914.06%
Revenue Next 2Y642.07%
Revenue Next 3Y367.52%
Revenue Next 5Y192.07%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
AUTL reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AUTL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
AUTL's earnings are expected to grow with 28.06% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.37%
EPS Next 3Y28.06%
5. Dividend
5.1 Amount
No dividends for AUTL!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AUTOLUS THERAPEUTICS PLC
NASDAQ:AUTL (5/2/2024, 5:41:45 PM)
After market: 4.11 0 (0%)4.11
+0.11 (+2.75%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.09B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -55.51% | ||
| ROE | -186.93% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 6.15 | ||
| Quick Ratio | 6.15 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)23.52%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y45.49%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-73.31%
Revenue growth 3Y-0.43%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y